Results 151 to 160 of about 280,575 (305)
ABSTRACT Background Although NCCN guidelines recommend preoperative therapy for borderline resectable pancreatic cancer (BR‐PC), it is still unclear which regimen is better. The study objective was to elucidate the prognostic significance of neoadjuvant chemoradiotherapy (NACRT) with gemcitabine/nab‐paclitaxel (GnP‐RT) compared to gemcitabine alone ...
Hirofumi Akita +9 more
wiley +1 more source
Chemotherapy treatment for HER2 positive and triple negative breast cancer
Breast cancer is the most prevalent cancer among women worldwide. This thesis will represent the neoadjuvant and adjuvant chemotherapy treatment for triple negative breast cancer and HER2 positive breast cancer.
Kahala, Dolev
core
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya +2 more
wiley +1 more source
Using a nationwide Japanese inpatient database, we evaluated whether broad‐spectrum antibiotic prophylaxis improves postoperative outcomes after pancreatoduodenectomy compared with narrow‐spectrum antibiotics. In propensity score–weighted analyses of 45 099 patients, broad‐spectrum prophylaxis was associated with significantly lower rates of intra ...
Hiroki Kitagawa +10 more
wiley +1 more source
ABSTRACT Background Determining whether to resect disappearing liver metastases (DLMs) after chemotherapy for colorectal liver metastases (CRLMs) remains challenging. Methods Patients who underwent hepatectomy after systemic chemotherapy for initially unresectable CRLMs were reviewed. True complete response (CR) was defined as either resected DLMs with
Taihei Soma +9 more
wiley +1 more source
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund +4 more
wiley +1 more source
In this multicenter retrospective study conducted by the Biliary Tract Club, we compared survival outcomes between gemcitabine–cisplatin–S‐1 (GCS) and gemcitabine–cisplatin (GC) in patients with unresectable biliary tract cancer, with a particular focus on conversion surgery. GCS was associated with longer overall and progression‐free survival compared
Hisashi Kosaka +27 more
wiley +1 more source
ABSTRACT Aim A novel systemic inflammatory response marker, the neutrophil × monocyte value (NM value), has been identified as a negative predictive factor for responses to chemoradiotherapy in rectal cancer. However, the clinical implications of the NM value remain unknown.
Takayoshi Sasaki +9 more
wiley +1 more source
Abstract Background A methodology to assess the immune microenvironment (IME) of non‐small cell lung cancer (NSCLC) has not been established, and the prognostic impact of IME factors is not yet clear. Aims This study aimed to assess the IME factors and evaluate their prognostic values. Methods and Results We assessed CD8+ tumor‐infiltrating lymphocyte (
Yukihiro Terada +16 more
wiley +1 more source
Surgical resection for CRLM seems to be as effective in elderly patients aged ≥ 80 as in nonelderly patients. However, elderly patients aged ≥ 80 had significantly worse cancer‐specific survival (CSS) and overall survival (OS). The significantly worse CSS and OS may have resulted from a lower rate of treatment for recurrence in elderly patients aged ...
Kiichi Sugimoto +7 more
wiley +1 more source

